| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Non-Customized |
|
Still deciding? Get samples of US$ 25/kg
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Product Description:
Levosimendan
Levosimendan is a calcium sensitizer and a selective phosphodiesterase III inhibitor used in the treatment of acute heart failure. It enhances cardiac contractility by sensitizing troponin C to calcium, thereby improving cardiac output without significantly increasing myocardial oxygen consumption. Levosimendan also exhibits vasodilatory effects by opening ATP-sensitive potassium channels in vascular smooth muscle, which leads to a reduction in preload and afterload. The drug is typically administered intravenously and is known for its relatively long duration of action due to its active metabolite, OR-1896.
Function:
Calcium Sensitization: Levosimendan increases the sensitivity of cardiac troponin C to calcium, enhancing the contractility of the heart muscle without raising intracellular calcium levels. This mechanism helps improve cardiac output and efficiency.
Phosphodiesterase III Inhibition: By inhibiting phosphodiesterase III, Levosimendan increases intracellular cAMP levels, leading to vasodilation and reduced vascular resistance. This contributes to its overall hemodynamic benefits.
Vasodilation: Levosimendan induces vasodilation by activating ATP-sensitive potassium channels in vascular smooth muscle. This action reduces both preload and afterload, thereby decreasing the workload on the heart.
Cardioprotective Effects: The drug has been shown to have cardioprotective effects, possibly due to its ability to enhance myocardial energetics and reduce myocardial ischemia.
Application:
Acute Heart Failure: Levosimendan is primarily used in the treatment of acute decompensated heart failure, particularly in patients with reduced cardiac output and low ejection fraction. It is administered in hospital settings, often in intensive care units, to stabilize critically ill patients.
Cardiogenic Shock: The drug is employed in managing cardiogenic shock, where it helps improve cardiac function and hemodynamics. It is especially useful in patients who do not respond adequately to conventional inotropic agents.
Perioperative Cardiac Support: Levosimendan is sometimes used in the perioperative setting to support patients undergoing cardiac surgery, particularly those with pre-existing heart failure or at high risk of post-operative complications.
Bridge to Transplantation: In patients awaiting heart transplantation, Levosimendan may be used as a bridge therapy to improve cardiac function and stabilize the patient's condition.
Severe Chronic Heart Failure: Although primarily used for acute cases, Levosimendan is occasionally utilized in the management of severe chronic heart failure, particularly in cases with episodic worsening or during hospital admissions.
Research and Clinical Trials: Levosimendan is being studied in various clinical trials to explore its potential benefits in different cardiovascular conditions, including septic shock, pulmonary hypertension, and right heart failure.
Off-Label Uses: Due to its unique mechanism of action, Levosimendan is sometimes used off-label for conditions where enhanced myocardial contractility and vasodilation are desired, under the guidance of a specialist.
Veterinary Medicine: Levosimendan is also used in veterinary medicine, particularly in dogs with congestive heart failure, to improve cardiac output and overall quality of life.
){kind=link}